Oncotrace RGCC is used to identify a primary tumour in a patient and to provide guidance about disease progression and future prognosis.
During the test, a sample of blood is analysed to identify the presence and concentration of circulating tumour cells (CTCs) and their concentration. This test provides information about the presence of CTCs, their concentration and their specific type (immunophenotype).
The results of the test enable clinicians to identify the origin of a tumour where this is unknown and to provide information on the development of cancer and the prognosis.
Test details
Sample type
Whole peripheral blood sample
Analysis period
Approx. 7 days
Cancer type
Applicable for all cancer types
Final results
7-10 days after sample delivery
Sample size
10-15 ml peripheral whole blood
Price*
800 €
* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.
* RGCC is not liable for any third-party comments or claims regarding our products. For accurate and up-to-date information about our offerings, please refer to our official website: rgcc-international.com
